---
layout: default
title: Colistimethate
parent: 僅模型預測 (L5)
nav_order: 208
evidence_level: L5
indication_count: 10
---

# Colistimethate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Colistimethate: From Gram-Negative Bacterial Infections to Osteoarthritis

## One-Sentence Summary

Colistimethate (colistin/polymyxin E prodrug) is a cationic polypeptide antibiotic historically used against multidrug-resistant Gram-negative bacterial infections. The TxGNN model predicts it may be effective for **Osteoarthritis**, but this prediction is currently supported by **0 clinical trials** and **0 publications** — it rests entirely on knowledge-graph embedding similarity, with no mechanistic or clinical corroboration found.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Multidrug-resistant Gram-negative bacterial infections (based on known pharmacological classification; no India/Taiwan regulatory license record available) |
| Predicted New Indication | Osteoarthritis |
| TxGNN Prediction Score | 97.78% |
| Evidence Level | L5 |
| India Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available for this candidate ([Data Gap] in the evidence pack). Based on known pharmacological information, colistimethate is a prodrug of colistin, a cationic polypeptide antibiotic that binds lipopolysaccharide (LPS) on the outer membrane of Gram-negative bacteria and disrupts membrane integrity to achieve bactericidal effect. This is a purely antibacterial mechanism.

Osteoarthritis pathology is driven by cartilage degeneration and mechanical wear, with no established antimicrobial or LPS-related component in its core disease process. The evidence pack's own repurposing rationale for this candidate explicitly states there is **no known molecular connection** between colistimethate's mechanism and osteoarthritis, and that the TxGNN score reflects only knowledge-graph embedding similarity rather than a validated biological link.

Given the absence of MOA confirmation, clinical trials, and literature, this prediction should be treated as a hypothesis-generation signal only, not as evidence of therapeutic plausibility. The same caveat applies to the other 9 predicted indications in this evidence pack (rheumatoid arthritis, osteoarthritis susceptibility, gout, pseudoachondroplasia, hepatic porphyria, brachyolmia, primitive portal vein thrombosis, hepatopulmonary syndrome, hepatoportal sclerosis) — all are scored L5/S0 with no corroborating mechanistic, clinical, or literature evidence.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Safety Considerations

**Drug Interactions** (33 total interactions on record; major examples below):

- **Major risk (nephrotoxicity/neurotoxicity synergy)**: Kanamycin, Neomycin, Streptomycin (concurrent aminoglycosides); Deferasirox; iodinated contrast media — Diatrizoate, Iodipamide, Iodixanol, Iohexol, Iopamidol, Iopromide, Iothalamic acid, Ioversol, Ioxilan (increased nephrotoxicity risk with contrast agents)
- **Moderate risk**: Mesalazine, Balsalazide, Olsalazine, Sulfasalazine (aminosalicylates), Vancomycin, Exenatide, Picosulfuric acid

Detailed key warnings and contraindications (e.g., TFDA/local label warnings) are not currently available in this evidence pack — this is flagged as a **Blocking** data gap (DG001) that prevents completion of the S1 safety pre-screen.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This candidate carries only an L5 (model-prediction-only) evidence level with an S0 decision stage — there are zero supporting clinical trials or publications, and the candidate's own mechanistic rationale explicitly finds no biological connection between colistimethate's antibacterial mode of action and osteoarthritis. A Blocking-severity data gap (missing label warnings/contraindications) also prevents any safety pre-screen from being completed.

**To proceed, the following is needed:**
- TFDA/local product label (warnings, contraindications) — required before any S1 safety screening (DG001, Blocking)
- Confirmed mechanism of action data via DrugBank or primary literature (DG002, High)
- At minimum, preclinical/mechanistic studies linking colistin-class antibiotics to osteoarthritis pathology before further investment
- Ongoing monitoring for any emerging clinical trial or literature evidence for this drug-disease pair
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

